On September 21, 2022 AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reported that Michael Bailey, president and chief executive officer, will participate in a panel discussion at the Cantor Fitzgerald Oncology & HemOnc Conference (Press release, AVEO, SEP 21, 2022, View Source [SID1234621291]). The panel titled "Building Combinations: What are the Novel Ideas?" will be held on Wednesday, September 28th, at 10:40 a.m. eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

If you are interested in arranging a 1×1 meeting at the conference, please contact your Cantor representative. For more details, please see the Calendar of Events section of AVEO Oncology’s corporate website.